Drugs / Ruvidar
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03945162 | Aug 2019 → Dec 2026 expected | urinary bladder carcinoma | Theralase® Technologies Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 69
| Date | Issuer | Release |
|---|---|---|
| 2026-03-17 | Theralase® Technologies Inc. | Results Theralase(R) Discovers Further Mechanism on How Ruvidar(R) Inactivates Herpes Simplex Virus theralase.com ↗
An additional MOA to be investigated was the electrostatic attraction between positively charged Ruvidar® and negatively charged HSV-1. |
| 2026-03-02 | Theralase® Technologies Inc. | Results Light-Activated Ruvidar and Interferon Demonstrate Enhanced Efficacy theralase.com ↗ |
| 2026-02-20 | Theralase® Technologies Inc. | Results Theralase Bladder Cancer Clinical Data to be Presented at the 2026 European Association of Urology Congress theralase.com ↗
The interim clinical data supports potential safety and efficacy of the treatment with 2 out of 3 patients obtaining a complete response and 2 out of 5 patients maintaining that complete response for 15 months or more. |
| 2026-02-10 | Theralase® Technologies Inc. | Results Theralase(R) Bladder Cancer Clinical Data to be Presented at the 2026 American Urological Association Annual Meeting theralase.com ↗
The interim clinical data supports the safety and efficacy of the treatment with 2 out of 3 patients obtaining a complete response and 2 out of 5 patients maintaining that complete response for 15 months or more. |
| 2026-02-04 | Theralase® Technologies Inc. | Results Theralase® Provides Update on Bladder Cancer Clinical Study theralase.com ↗
Interim clinical data has exceeded the recommended guidelines of the International Bladder Cancer Group for complete response and duration of complete response |
| 2025-11-17 | Theralase® Technologies Inc. | Results Theralase® Investor Conference Call Reminder theralase.com ↗
Theralase(R) Reminds Investors of Conference Call to Provide Update on Study II Interim Data Demonstrating 64.3% Complete Response |
| 2025-09-24 | Theralase® Technologies Inc. | Results Independent Research Demonstrates Ruvidar(R) Effective in the Destruction of Herpes Simplex Virus theralase.com ↗
This peer-reviewed publication provides strong support that Ruvidar is more effective in the treatment of HSV-1 than either Acyclovir® or Metformin®, even without light-activation. |
| 2025-05-20 | Theralase® Technologies Inc. | Results Theralase® Provides Corporate Update theralase.com ↗
According to this definition, 69 patients have completed Study II (with 13 patients on study with pending clinical data) resulting in the following interim clinical data in support of the Study II endpoints. |
| 2025-05-05 | Theralase® Technologies Inc. | Results Theralase® Clinical Data Presented at Canadian Bladder Cancer Forum and American Urological Association theralase.com ↗ |
| 2025-04-28 | Theralase® Technologies Inc. | Results Theralase® Discovers New Mechanism of Action of Lead Drug theralase.com ↗
Theralase® Has Discovered a New Mechanism of Action in Its War on Cancer; Specifically, Ruvidar’s(TM) Ability to Inhibit DeUbiquitinating Enzymes, an Important Class of Enzymes Which Have Been Linked to Numerous Cancers and Neurogenerative Diseases |
| 2025-04-10 | Theralase® Technologies Inc. | Results Ruvidar More Effective in the Treatment of Herpes than FDA-Approved Treatments theralase.com ↗
Ruvidar demonstrates higher efficacy in the treatment of Herpes Simplex Virus, Type 1 versus FDA-approved, standard of care treatments Acyclovir and Abreva in a preclinical animal model. |
| 2025-04-07 | Theralase® Technologies Inc. | Results Ruvidar Demonstrates 7 Year Complete Response theralase.com ↗
Patient Diagnosed with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In-Situ Treated Once with Light-Activated Ruvidar(TM) Demonstrates 7 Year Complete Response |
| 2025-03-24 | Theralase® Technologies Inc. | Results Ruvidar Effective in the Treatment of Herpes theralase.com ↗
Ruvidar demonstrates higher efficacy in the treatment of Herpes Simplex Virus, Type 1 versus the standard of care treatments Acyclovir and Abreva in a preclinical animal model. |
| 2025-02-13 | Theralase® Technologies Inc. | Results CORRECTING AND REPLACING: Theralase® Demonstrates Effective Treatment of Herpes theralase.com ↗
Theralase® validates previous University of Manitoba research by demonstrating that Ruvidar is safe and effective in the treatment of the Herpes Simplex Virus in an animal model. |
| 2025-02-12 | Theralase® Technologies Inc. | Results Theralase® Demonstrates Effective Treatment of Herpes theralase.com ↗
Theralase® validates previous University of Manitoba research by demonstrating that Ruvidar is safe and effective in the treatment of the Herpes Simplex Virus in an animal model. |
| 2025-02-10 | Theralase® Technologies Inc. | Results Theralase® Releases Latest Research on Inactivation of Herpes Simplex Viruses theralase.com ↗
University of Manitoba independent research verifies that Ruvidar is more effective than acyclovir in the inactivation of Herpes Simplex Viruses post infection. |
| 2025-01-27 | Theralase® Technologies Inc. | Results Theralase® Interim Clinical Data to be Presented at the 2025 AUA Annual Meeting theralase.com ↗
The interim clinical data supports the high safety and efficacy of the treatment with a number of patients demonstrating a duration of response of 3 years or greater with a single treatment. |
| 2024-09-03 | Theralase® Technologies Inc. | Results Ruvidar™ Proven More Effective Than Acyclovir in Destruction of Herpes Simplex Virus theralase.com ↗ |
| 2024-06-14 | Theralase® Technologies Inc. | Results Ruvidar Enhances Efficacy of Cancer Drug theralase.com ↗
In cell-based experiments, the new compound, nicknamed RuBCG, was able to significantly increase the efficacy of BCG in cancer cell kill versus BCG or Ruvidar alone, when non-light activated. |
| 2024-06-06 | Theralase® Technologies Inc. | Results Theralase® Successfully Destroys Lung Cancer theralase.com ↗
Theralase® has demonstrated that all animals treated with x-ray activated Rutherrin® are currently alive; unfortunately, this is not the case for mice that received x-ray treatment only. |
| 2024-06-04 | Theralase® Technologies Inc. | Results Theralase® Technology Effective in Virus Inactivation theralase.com ↗
The research, which demonstrated that Ruvidar was effective at inactivating both enveloped and non-enveloped viruses, alone and when light activated was recently accepted in a peer-reviewed publication, Heliyon, and can be reviewed at TM https://doi.org/10.1016/j.heliyon.2024.e32140 |
| 2024-04-12 | Theralase® Technologies Inc. | Results Theralase® to Host Advisory Board Meetings at Canadian Urological Association Bladder Cancer Forum and the American Urological Association theralase.com ↗
The current interim Phase II clinical study analysis demonstrates a significant clinical advantage of the Theralase® technology in the current treatment landscape and provides potential for a novel, effective and lasting treatment option for these patients. |
| 2023-10-16 | Theralase® Technologies Inc. | Results Theralase® Provides Update on Bladder Cancer Clinical Study theralase.com ↗ |
| 2023-05-10 | Theralase® Technologies Inc. | Results Theralase® Provides Update on Phase II Bladder Cancer Study theralase.com ↗
For the primary objective, 65% of Evaluable Patients (Patients evaluated by a Principal Investigator (“PI”)) achieved a Complete Response (“CR”) at any assessment date post primary Study Treatment and 30% of Evaluable Patients achieved a CR at 450 days. |
| 2023-03-31 | Theralase® Technologies Inc. | Results Theralase® Releases Corrected and Restated Press Release for 1Q2023 Interim Financial Statements theralase.com ↗
In the Performance to Primary, Secondary and Tertiary Objectives second table the 90 day results were misstated and has been corrected in this press release. |
| 2023-02-23 | Theralase® Technologies Inc. | Results Theralase® Phase II NMIBC Clinical Study (Interim) Data Presented at the ASCO GU Cancer Symposium theralase.com ↗
I am encouraged by the positive interim results of the light-activated, intravesical study drug TLD-1433 (Trade Name: Ruvidar) currently under investigation by Theralase® in Study II. |
| 2022-06-21 | Theralase® Technologies Inc. | Results Theralase® Phase Ib NMIBC Clinical Study Published theralase.com ↗
Although limited by the small sample size typically inherent in phase 1 trials, we feel that the photosensitizer TLD-1433 and the delivery device TLC-3200 hold promise for the treatment of NMIBC. |
| 2022-04-05 | Theralase® Technologies Inc. | Results Theralase® Provides Update on Phase II Bladder Cancer Clinical Study theralase.com ↗
To date, Study II has enrolled and provided the primary study treatment for 35 patients, which when combined with the Study I data, leads to a total of 38 patients, who have received at a minimum, the primary study treatment. |
| 2020-11-23 | Theralase® Technologies Inc. | Regulatory Theralase Granted FDA Fast Track Designation for NMIBC Phase II Clinical Study theralase.com ↗
the U.S. Food and Drug Administration (“ ”) has granted Theralase® Fast Track Designation (“ ”) for its Phase II Bacillus Calmete Guérin (“ ”) Unresponsive Non-Muscle Invasive Bladder Cancer (“ ”) Carcinoma In Situ (“ ”) clinical study (“ ”). |
| 2020-09-24 | Theralase® Technologies Inc. | Results Theralase Provides Update on Bladder Cancer Study theralase.com ↗
3 out of 12 patients (25%) have demonstrated a Partial Response (“ ”) (2 patients with negative cystoscopy and positive urine cytology and 1 patient with positive cystoscopy and negative urine cytology), with 2 of these patients having received second treatment. PR |
| 2020-08-01 | Theralase® Technologies Inc. | Results Theralase® Provides Update on Phase II Bladder Cancer Clinical Study theralase.com ↗
The Study II interim clinical data demonstrates a Complete Response (“ ”) of 54% at 6 months, 38% at 12 months and 37% at 15 months, which exceeds the IBCG guidelines. |
| 2020-07-30 | Theralase® Technologies Inc. | Results Theralase Reports on Phase II Non-Muscle Invasive Bladder Cancer (“NMIBC”) Clinical Study (“Study II”) Progress theralase.com ↗
Results of the First 12 patients enrolled in the Phase II NMIBC Clinical Study Demonstrate a 58.3% Response 90 Days Post Initial Treatment |
| 2019-10-01 | Theralase® Technologies Inc. | Regulatory Theralase Files Investigational New Drug Application with the FDA theralase.com ↗
the Company has filed an Investigational New Drug (“ ”) application with the U.S. Food and Drug Administration (“ ”) to initiate a Phase II, Non-Muscle Invasive Bladder Cancer (“ ”) clinical study |
| 2019-09-30 | Theralase® Technologies Inc. | Results Patient Six Cancer-Free Eighteen Months After Single Anti-Cancer Treatment theralase.com ↗
Patient six has demonstrated no tumour recurrence, progression or presence of NMIBC disease at the 90, 180, 270, 360 and now 540 days post treatment clinical cystoscopy assessment and urine cytology, marking a new milestone for the Company. |
| 2019-07-31 | Theralase® Technologies Inc. | Results Patient Five Cancer-Free Eighteen Months After Single Anti-Cancer Treatment theralase.com ↗
Patient five has demonstrated no tumour recurrence, progression or presence of NMIBC disease at the 90, 180, 270, 360 and now 540 days post treatment clinical and cystoscopy assessment, marking a new achievement for the Company. |
| 2019-06-28 | Theralase® Technologies Inc. | Results Theralase Releases 2019 Annual General Meeting Video Presentations theralase.com ↗
The successfully completed Phase Ib NMIBC clinical study demonstrated Complete Response (“ ”) in two patients treated at the therapeutic dose (0.70 mg/cm ) at 360 days post initial single treatment. |
| 2019-06-26 | Theralase® Technologies Inc. | Regulatory Health Canada Approves Amended Clinical Trial Application theralase.com ↗
Health Canada has issued a No Objection Letter (“ ”) for an amended Clinical Trial Application (“ ”) for its Phase II Non-Muscle Invasive Bladder Cancer (“ ”) clinical study (“ ”). |
| 2019-04-02 | Theralase® Technologies Inc. | Results Patient Six Cancer-Free Twelve Months After Single Anti-Cancer Treatment theralase.com ↗
The Company is pleased to report that patient five and six have continued to demonstrate no tumour recurrence, progression or presence of NMIBC disease at 360 days post treatment during their scheduled clinical and cystoscopy assessment. |
| 2019-01-31 | Theralase® Technologies Inc. | Results Theralase® Patient Five Cancer-Free Twelve Months After Single Anti-Cancer Treatment theralase.com ↗
Patient five has demonstrated no tumour recurrence or presence of disease at the 90, 180, 270 and now 360 days post treatment clinical and cystoscopy assessment, marking a new achievement for the Company. |
| 2018-12-10 | Theralase® Technologies Inc. | Regulatory Health Canada Grants ITA Approval to Commence Phase II Clinical Study theralase.com ↗ |
| 2018-11-08 | Theralase® Technologies Inc. | Results Patient Five Cancer-Free After Single PDT Treatment theralase.com ↗ |
| 2018-09-10 | Theralase® Technologies Inc. | Regulatory Health Canada Approves Commencement of Phase II Clinical Study theralase.com ↗ |
| 2018-08-27 | Theralase® Technologies Inc. | Results Theralase® Provides Corporate Update theralase.com ↗
These results compelled the independent Medical and Scientific Advisory Board (“ ”) to recommend to the Company, the early termination of the Study due to achievement of the primary and secondary endpoints. |
| 2018-05-30 | Theralase® Technologies Inc. | Results Theralase® Successfully Completes Phase Ib Non-Muscle Invasive Bladder Cancer Clinical Study theralase.com ↗ |
| 2018-05-17 | Theralase® Technologies Inc. | Results Theralase® Provides Update on Phase Ib Non-Muscle Invasive Bladder Cancer Clinical Study theralase.com ↗
Patient Six Demonstrates No Clinical Evidence of NMIBC at 90 Day Cystoscopy Analysis |
| 2018-04-16 | Theralase® Technologies Inc. | Results Theralase® Provides Update on Phase Ib Non-Muscle Invasive Bladder Cancer Clinical Study theralase.com ↗
Patient Five Shows No Clinical Evidence or Presence of NMIBC at 90 Day Cystoscopy Analysis |
| 2018-03-15 | Theralase® Technologies Inc. | Results Theralase® Anti-Cancer Technology Effective in Destroying Brain Cancer Stem Cells theralase.com ↗
TLD-1433, combined with transferrin to form Rutherrin , has been demonstrated to effectively destroy human brain cancer stem cells. |
| 2018-03-05 | Theralase® Technologies Inc. | Results Theralase® Advances Anti-Cancer Technology in Destruction of Human Lung Cancer theralase.com ↗
announced today that its lead compound, TLD-1433, when combined with transferrin to form Rutherrin , has been demonstrated to target and effectively kill human lung cancer cells, in two preclinical animal models. |
| 2018-01-17 | Theralase® Technologies Inc. | Results Theralase® Optimizes Delivery Schedule of Anti-Cancer Vaccine in Destruction of Brain Cancer theralase.com ↗
The latest data obtained on the optimized delivery timetable (six vaccinations versus two vaccinations) demonstrated a material increase in the survival of animals from 35% to 87.5%. |
| 2017-11-08 | Theralase® Technologies Inc. | Results Theralase® Provides Interim Data Analysis on Anti-Cancer Treatment for First Four Patients Treated theralase.com ↗
First Four Patients Treated with Company’s Anti-Cancer Treatment Achieve Pre-Defined Primary, Secondary and Exploratory Outcome Measures |
| 2017-09-25 | Theralase® Technologies Inc. | Results Theralase® Lead Anti-Cancer Drug Effective in the Destruction of Brain Cancer when Activated by X-Rays theralase.com ↗
TLD-1433, when activated by X-rays, has been demonstrated preclinically, to be effective in the destruction of human GlioBlastoma Multiforme (“ ”) cancer cells, a deadly form of brain cancer. |
| 2017-09-19 | Theralase® Technologies Inc. | Results Theralase Lead Anti-Cancer Drug Effective in the Destruction of Throat Cancer theralase.com ↗
The dark toxicity (TLD-1433, but no laser light applied) was virtually negligible |
| 2017-09-05 | Theralase® Technologies Inc. | Results Theralase Anti-Cancer Drugs Effective in the Destruction of Cervical Cancer theralase.com ↗
announced today that its patented, lead anti-cancer drug, TLD-1433, has been proven effective in the destruction of a human cervical carcinoma cell line, ME180. |
| 2017-08-08 | Theralase® Technologies Inc. | Results Theralase Anti-Cancer Technology Effective for the Destruction of Lung Cancer theralase.com ↗
TLD-1433, in combination with transferrin (Rutherrin®) has been shown to selectively accumulate in cancerous tumours versus healthy tissue, due to localization through the Tf-R. |
| 2017-07-25 | Theralase® Technologies Inc. | Results Theralase Achieves Exploratory Endpoint of Efficacy for Anti-Cancer Technology theralase.com ↗
The exploratory efficacy endpoint is being reported at ninety (90) days, in the first 3 patients treated, in the first part of a Phase Ib clinical study (“ “). |
| 2017-06-15 | Theralase® Technologies Inc. | Results Theralase Presents Phosphorescent Photosensitizers at International World Congress theralase.com ↗
It is able to localize to the mitochondria of T-24 human bladder cancer cells and not the nucleus (Effective way to kill cancer cells without nuclear damage) |
| 2016-10-20 | Theralase® Technologies Inc. | Regulatory Health Canada Grants Theralase ITA Approval theralase.com ↗
Theralase, possessing both CTA and ITA approval, plans to immediately commence a Phase Ib clinical study for the treatment of NMIBC. |
| 2016-06-20 | Theralase® Technologies Inc. | Regulatory Theralase Granted US Patent for Lead Anti-Cancer Drug theralase.com ↗ |
| 2016-05-11 | Theralase® Technologies Inc. | Results Theralase Presents Anti-Cancer Technology at 111th Annual American Urological Association Meeting theralase.com ↗
These findings have demonstrated why our novel photosensitizer TLD-1433 should be evaluated in a Phase Ib clinical trial of Photo Dynamic Therapy (“ ”) for NMIBC. |
| 2016-04-15 | Theralase® Technologies Inc. | Results Theralase Research Published in International Peer-Reviewed Journal theralase.com ↗
The latest research demonstrates that TLD-1433, mixed with transferrin, reduces the toxicity of TLD-1433 and improves the overall efficacy in the destruction of cancer cells. |
| 2015-12-17 | Theralase® Technologies Inc. | Regulatory Health Canada Approves Clinical Trial Application for Anti-Cancer Drug theralase.com ↗
Health Canada has approved its next generation anti-cancer drug, TLD-1433, under Clinical Trial Application (“CTA”) for evaluation in a Phase Ib clinical trial for patients inflicted with Non-Muscle Invasive Bladder Cancer (“NMIBC”). |
| 2015-09-21 | Theralase® Technologies Inc. | Regulatory Theralase Submits Anti-Cancer Technology to Research Ethics Board for Approval theralase.com ↗
Pending approval of the following applications, UHN will commence enrolling patients: |
| 2015-09-18 | Theralase® Technologies Inc. | Regulatory Theralase Submits Investigational Testing Authorization to Health Canada for Approval theralase.com ↗
The submission of an ITA to Health Canada for NMIBC is yet another advancement for the Company in its quest to prove the safety, tolerability and efficacy of its anti-cancer technology in the destruction of NMIBC. |
| 2015-09-17 | Theralase® Technologies Inc. | Regulatory Theralase Submits Clinical Trial Application to Health Canada for Approval theralase.com ↗
announced today that it has submitted a Clinical Trial Application (“ ”) for its anti-cancer technology to Health Canada for approval. |
| 2015-09-09 | Theralase® Technologies Inc. | Results Theralase Research Demonstrates Lead Drug Also Effective for Muscle Invasive Bladder Cancer theralase.com ↗ |
| 2015-05-27 | Theralase® Technologies Inc. | Results Theralase Presents Latest Scientific Research at 15th International Photodynamic Association World Congress theralase.com ↗
The latest research details the dramatic increase in targeting and efficacy in the destruction of cancer of Theralase’s lead Photo Dynamic Compound (“ ”) TLD-1433 when bound to transferrin, in a presentation entitled, “Novel biophysical properties of photosensitizer TLD-1433 upon binding to transferrin” PDC |
| 2015-04-02 | Theralase® Technologies Inc. | Regulatory Theralase Holds pre-CTA Meeting with Health Canada theralase.com ↗
announced today that it recently held a pre “Clinical Trial Application” (“ ”) consultation meeting with Health Canada |
| 2015-02-23 | Theralase® Technologies Inc. | Results Theralase Identifies Potential Mechanism of How Lead Anti-Cancer Drug Works to Destroy Cancer and Discovers New Application to Detect Cancer Cells theralase.com ↗
Rutherrin has demonstrated an ability to significantly increase the targeting of bladder cancer cells and in the process, significantly increase the efficacy and safety of the treatment procedure. |
| 2015-02-13 | Theralase® Technologies Inc. | Results Theralase’s Lead Anti-Cancer Drug Has Significantly Less Skin Toxicity than FDA Approved Drug theralase.com ↗
TLD-1433 produced 10,000,000 times less Reactive Oxygen Species (“ ”) in the skin than Photofrin®; therefore, providing a much higher safety margin to light sensitivity than Photofrin® allowing patients the opportunity post treatment to enter direct sunlight within days and not months. |
All press releases naming this drug 71 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ruvidar | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03945162 ↗ |
| Known as | TLD-1433 | “Ruvidar® (TLD-1433) for intravesical administration is supplied as a lyophilisate for suspension in Sterile Water For Injection” NCT03945162 ↗ |